Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Why Fitbit Stock Is Soaring Today
Why Fitbit Stock Is Soaring Today
Shares of fitness wearables company Fitbit (NYSE: FIT) surged on Thursday following the announcement of a partnership with medical-device maker DexCom (NASDAQ: DXCM) related to glucose monitoring.....
Why Illumina Rose 18.7% in August
Why Illumina Rose 18.7% in August
Shares of Illumina (NASDAQ: ILMN), a leading manufacturer of genetic testing equipment, rose 18.7% in August, according to data from S&P Global Market Intelligence. Investors can thank solid....
5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
It's been a busy week for biotech and healthcare conferences. Drugmakers big and small have been making the rounds, answering questions about their current status and future prospects. Celgene....
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE). On Wednesday, several of the company's top....
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company....
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....
Why Kite Pharma Soared 64.8% in August
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
Why Sarepta Therapeutics Stock Is Rising Today
Why Sarepta Therapeutics Stock Is Rising Today
Shares of mid-cap biotech Sarepta Therapeutics (NASDAQ: SRPT) marched almost 11% higher Wednesday morning on elevated volume. The stock's rally was catalyzed by news of encouraging results from an....
Here's Why Novo Nordisk A/S Gained 12% in August
Here's Why Novo Nordisk A/S Gained 12% in August
Shares of Danish pharma giant Novo Nordisk A/S (NYSE: NVO) rose 11.7% in August, according to data from S&P Global Market Intelligence. Investors were relieved to see that the sales stall the....
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
Image source: Getty Images.Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky -- nearly four-tenths of the way to the moon. That stack would total $1.4....
Why Exact Sciences Shares Rallied 10.2% in August
Why Exact Sciences Shares Rallied 10.2% in August
After the company reported better-than-expected top- and bottom-line second-quarter results in late July and updated investors on its strategy at Cannacord's 37th annual growth conference on Aug.....
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
Investors have been wondering for a few years now when Gilead Sciences (NASDAQ: GILD) would spend some of its massive cash hoard and acquire a new company, and this week, Gilead put those wonders....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
I bought my shares of Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) long ago, when they were trading far lower than they are today. If I had to choose one to keep and....
Here's the Best Dividend Stock in Big Pharma
Here's the Best Dividend Stock in Big Pharma
Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for....
Why Gilead Sciences Shares Soared 10.6% in August
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
3 Biotech Stocks That Skyrocketed This Week
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
In a previous article, I laid out the bear case against Intuitive Surgical (NASDAQ: ISRG). Today, I'm looking at some ways the robotic surgery leader's stock could trend higher in the years....
3 Reasons Gilead Sciences Jumped to Buy Kite Pharma
3 Reasons Gilead Sciences Jumped to Buy Kite Pharma
Gilead Sciences Inc. (NASDAQ: GILD) might be the most disciplined capital allocator in biotech. For years, its management has resisted calls from the peanut gallery to make a big acquisition,....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE: LLY) was founded in 1876, while Pfizer Inc. (NYSE: PFE) began....
3 Stocks That Pay You
3 Stocks That Pay You
Other than the obvious reason that investors like the steady stream of income that comes from investing in dividend-paying stocks, the stability it conveys about a particular business provides a....
GlaxoSmithKline Is Wasting Money Paying a Dividend
GlaxoSmithKline Is Wasting Money Paying a Dividend
As a general rule, I love companies that pay big dividends -- and British pharmaceutical giant GlaxoSmithKline (NYSE: GSK) pays some of the best dividends on the planet. That said, there's one....